Krystal Biotech (NASDAQ:KRYS) Upgraded at Chardan Capital

Krystal Biotech (NASDAQ:KRYS) was upgraded by analysts at Chardan Capital to a “strong-buy” rating in a note issued to investors on Monday,Zacks.com reports.

KRYS has been the subject of a number of other research reports. Wall Street Zen downgraded shares of Krystal Biotech from a “buy” rating to a “hold” rating in a research report on Saturday, June 20th. Citigroup upped their price target on shares of Krystal Biotech from $378.00 to $386.00 and gave the stock a “buy” rating in a research note on Tuesday. HC Wainwright increased their price objective on Krystal Biotech from $310.00 to $361.00 and gave the stock a “buy” rating in a report on Tuesday, June 16th. Weiss Ratings upgraded Krystal Biotech from a “buy (b-)” rating to a “buy (b)” rating in a research note on Monday. Finally, Bank of America upped their target price on Krystal Biotech from $364.00 to $396.00 and gave the stock a “buy” rating in a research report on Tuesday, July 14th. One research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating and two have issued a Hold rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $361.56.

Krystal Biotech Stock Performance

Krystal Biotech stock opened at $325.78 on Monday. Krystal Biotech has a 52 week low of $132.31 and a 52 week high of $382.54. The firm has a market capitalization of $9.64 billion, a price-to-earnings ratio of 40.82 and a beta of 0.53. The company has a 50 day moving average price of $340.79 and a 200 day moving average price of $297.13.

Krystal Biotech (NASDAQ:KRYS) last announced its earnings results on Monday, August 3rd. The company reported $1.79 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.70 by $0.09. The company had revenue of $119.22 million for the quarter, compared to the consensus estimate of $120.93 million. Krystal Biotech had a net margin of 54.82% and a return on equity of 19.34%. Equities analysts forecast that Krystal Biotech will post 7.27 earnings per share for the current fiscal year.

Insider Transactions at Krystal Biotech

In related news, EVP John Charles Thomas sold 1,000 shares of the business’s stock in a transaction on Thursday, June 25th. The stock was sold at an average price of $347.27, for a total value of $347,270.00. Following the sale, the executive vice president owned 1,000 shares of the company’s stock, valued at $347,270. The trade was a 50.00% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Suma Krishnan sold 25,000 shares of Krystal Biotech stock in a transaction that occurred on Thursday, June 4th. The shares were sold at an average price of $308.11, for a total transaction of $7,702,750.00. Following the completion of the transaction, the insider owned 1,378,155 shares of the company’s stock, valued at $424,623,337.05. This trade represents a 1.78% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders have sold 26,642 shares of company stock valued at $8,243,923. Corporate insiders own 13.10% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the company. Sound Income Strategies LLC lifted its position in Krystal Biotech by 1,270.0% in the 4th quarter. Sound Income Strategies LLC now owns 137 shares of the company’s stock valued at $34,000 after acquiring an additional 127 shares in the last quarter. Western Wealth Management LLC acquired a new stake in shares of Krystal Biotech in the 1st quarter valued at approximately $34,000. Greenline Wealth Management LLC acquired a new position in shares of Krystal Biotech during the 4th quarter worth about $34,000. Danske Bank A S bought a new stake in Krystal Biotech in the third quarter valued at approximately $35,000. Finally, UMB Bank n.a. lifted its holdings in Krystal Biotech by 34.6% during the 4th quarter. UMB Bank n.a. now owns 144 shares of the company’s stock valued at $36,000 after purchasing an additional 37 shares during the last quarter. Institutional investors own 86.29% of the company’s stock.

Krystal Biotech Company Profile

Krystal Biotech, Inc is a clinical-stage biotechnology company focused on developing gene therapies for rare dermatological diseases. Headquartered in Pittsburgh, Pennsylvania, the company applies proprietary viral vector delivery technology to enable topical administration of corrective genes directly to the skin. By targeting the underlying genetic causes of inherited skin disorders, Krystal Biotech seeks to address areas of high unmet medical need with potentially transformative treatments.

The company’s lead product candidate, KB103, is designed to deliver a functional COL7A1 gene to patients with dystrophic epidermolysis bullosa (DEB), a severe and often debilitating blistering condition.